Genelux Corporation to Participate in Upcoming Conferences

Core Insights - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for patients with aggressive and difficult-to-treat solid tumors [3] Company Participation in Conferences - Genelux will participate in the Oppenheimer Healthcare Life Sciences Conference on February 25, 2026, featuring a virtual fireside chat with key executives [4] - The company will also present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, in Boston, MA [4] Clinical Trials - Olvi-Vec, Genelux's lead product, is currently being evaluated in two U.S.-based clinical trials: - OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer [3] - VIRO-25, a Phase 2 trial for non-small-cell lung cancer [3] - Additionally, Olvi-Vec is being evaluated in a China-based Phase 1b/2 trial for recurrent small-cell lung cancer [3] Proprietary Technology - The company's discovery and development efforts are centered around its proprietary CHOICE™ platform, which has led to the creation of an extensive library of oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec [3]